Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and...

Descripción completa

Detalles Bibliográficos
Autores principales: Maglione, Alessandro, Morra, Marta, Meroni, Raffaella, Matta, Manuela, Clerico, Marinella, Rolla, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957380/
https://www.ncbi.nlm.nih.gov/pubmed/35364386
http://dx.doi.org/10.1016/j.msard.2022.103776
_version_ 1784676752197419008
author Maglione, Alessandro
Morra, Marta
Meroni, Raffaella
Matta, Manuela
Clerico, Marinella
Rolla, Simona
author_facet Maglione, Alessandro
Morra, Marta
Meroni, Raffaella
Matta, Manuela
Clerico, Marinella
Rolla, Simona
author_sort Maglione, Alessandro
collection PubMed
description Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.
format Online
Article
Text
id pubmed-8957380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-89573802022-03-28 Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies Maglione, Alessandro Morra, Marta Meroni, Raffaella Matta, Manuela Clerico, Marinella Rolla, Simona Mult Scler Relat Disord Correspondence Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign. Elsevier B.V. 2022-05 2022-03-26 /pmc/articles/PMC8957380/ /pubmed/35364386 http://dx.doi.org/10.1016/j.msard.2022.103776 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Maglione, Alessandro
Morra, Marta
Meroni, Raffaella
Matta, Manuela
Clerico, Marinella
Rolla, Simona
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title_full Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title_fullStr Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title_full_unstemmed Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title_short Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
title_sort humoral response after the booster dose of anti-sars-cov-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957380/
https://www.ncbi.nlm.nih.gov/pubmed/35364386
http://dx.doi.org/10.1016/j.msard.2022.103776
work_keys_str_mv AT maglionealessandro humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies
AT morramarta humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies
AT meroniraffaella humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies
AT mattamanuela humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies
AT clericomarinella humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies
AT rollasimona humoralresponseaftertheboosterdoseofantisarscov2vaccineinmultiplesclerosispatientstreatedwithhighefficacytherapies

Ejemplares similares